As early as 1995 and 1996, the descriptions of alternatively spliced CD44 species were proposed between the normal, inflammatory and neoplastic lesions by Rosenberg and Yoshida, respectively, which first unravelled the mystery of CD44 variants in IBD patients.77, 78. This evidence concerns the gene CD44 and inflammatory bowel disease.